As IL-17 is a signature cytokine of these cell types, CRISP3 may both promote tumor cell proliferation via IL-17/AKT signaling and facilitate the recruitment or expansion of IL-17–producing immune cells, thereby reinforcing an immunosuppressive tumor microenvironment. Here, IL17A is linked to neoplasm.